Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results

Key Points

• Krystal Biotech exceeded quarterly expectations: The company reported adjusted EPS of $2.05, beating the $1.79 consensus estimate, while revenue reached $127.34 million versus expectations of $125.77 million. Net margin was 54.82% and return on equity was 19.34%.
• Analyst sentiment remains favorable: Krystal has a consensus “Moderate Buy” rating, with an average price target of $377.20; recent firms issued or maintained bullish ratings and targets as high as $474.
• Insiders recently sold shares: Insider Suma Krishnan and director Dino A. Rossi each sold 25,000 shares under reported transactions, while insiders collectively retain 13.10% ownership of the company.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) released its earnings results on Monday. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.79 by $0.26, FiscalAI reports. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The firm had revenue of $127.34 million for the quarter, compared to analysts' expectations of $125.77 million.

Krystal Biotech Price Performance

KRYS opened at $332.29 on Monday. The stock has a market capitalization of $9.84 billion, a price-to-earnings ratio of 41.64 and a beta of 0.50. Krystal Biotech has a twelve month low of $184.02 and a twelve month high of $382.54. The company has a 50-day simple moving average of $337.46 and a 200 day simple moving average of $308.68.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KRYS. Weiss Ratings upgraded Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, October 23rd. Royal Bank Of Canada began coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They set an "outperform" rating and a $400.00 target price for the company. Jefferies Financial Group reaffirmed a "buy" rating and set a $474.00 target price on shares of Krystal Biotech in a report on Monday, July 13th. Chardan Capital upgraded shares of Krystal Biotech to a "strong-buy" rating in a research report on Monday, August 3rd. Finally, Bank of America boosted their price objective on Krystal Biotech from $392.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Moderate Buy" and an average price target of $377.20.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company's stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. 13.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.